Emergent Biodefense Operations is investing $10.9 million in its Lansing facility.
Emergent Biodefense Operations is part of biopharmaceutical company Emergent Biosolutions. The $10.9 million will allow Emergent Biodefense Operations to develop and manufacture vaccine and immune-related therapeutics.
The majority of the funds will pay for additional equipment. The company has already spent more than $70 million to ready its Lansing facility for production, says Karl Dorshimer, vice president of the Lansing Economic Development Corporation (EDC).
The investment and expansion of operations is expected to create 93 jobs.
“In these times, I think we should be feeling quite good about how the city’s positioned,” says Bob Trezise, CEO of the Lansing EDC. The Emergent expansion and jobs announcement comes on the heels of Jackson National Life’s announcement to bring an additional 150 jobs to the city.
“People are hurting, there’s no question about that. Times are hard, but we continue to have jobs announcements and it’s a real diversification of our city,” Trezise says. “It’s positioning us well on a global scale,”
Source: Chelsea Niemiec, D+P Company
Ivy Hughes, development news editor, can be reached here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.